1 unchanged sentence
We have no information to disclose that was required
−Removed: to be disclosed in a report on Form 8-K during the three months ended March 31, 2026 but was not reported.
+Added: to be disclosed in a report on Form 8-K during the three months ended June 30, 2026 but was not reported.
There have been no material changes to the procedures
by which shareholders may recommend nominees to our board of directors since such procedures were last disclosed.
−Removed: None of our directors or executive officers
−Removed: adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation
−Removed: S-K) during the three months ended March 31, 2026.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the three months ended June 30, 2026.
Description of Exhibit
9 unchanged sentences
(incorporated by reference to Exhibit 2.3 to the Annual Report on Form 1-K filed on July 6, 2020)
+Added: 3.6 Amendment No.
+Added: 1 to Amended and Restated Bylaws of 20/20 Biolabs, Inc.
+Added: (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on May 26, 2026)
+Added: 4.1 Global Amendment, dated April 23, 2026, between Streeterville Capital, LLC and 20/20 Biolabs, Inc.
+Added: (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed on April 28, 2026)
4.2 Warrant to Purchase Shares of Common Stock issued by 20/20 Biolabs, Inc.
14 unchanged sentences
to StartEngine Primary, LLC on December 31, 2021 (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 1-K filed on April 30, 2025)
−Removed: Secured Convertible Promissory Note issued by 20/20 Biolabs, Inc.
−Removed: to Streeterville Capital, LLC on February 9, 2026 (incorporated by reference to Exhibit 10.2 to the Annual Report on Form 10-K filed on March 31, 2026)
31.1* Certifications of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
6 unchanged sentences
** Furnished herewith
−Removed: Pursuant to the requirements
−Removed: of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
−Removed: duly authorized.
−Removed: 20/20 BIOLABS, INC.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 14, 2026 20/20 BIOLABS, INC.
/s/ Jonathan Cohen
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.